Ad-hoc | 26 April 2005 10:10

STRATEC: Further margin growth with a significant rise in sales

Ad hoc announcement §15 WpHG Results STRATEC: Further margin growth with a significant rise in sales Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— Further margin growth with a significant rise in sales Birkenfeld, April 26, 2005 The Board of Management of STRATEC Biomedical Systems AG, listed in the German Prime Standard and in Gate-M, hereby announces the results for the first quarter of FY 2005, ending on March 31, 2005, pursuant to Section 15 of the German Securities Trading Law (WpHG). STRATEC increased its earnings to EUR 0.720m (2004: EUR 0.507m). This results in earnings per share (EPS) amounting to EUR 0.22 (2004: EUR 0.15). The diluted earnings per share are EUR 0.21 (2004: EUR 0.15). Sales was increased by 27.4% to EUR 10.097m (2004: EUR 7.928m). The overall performance improved by 23.2% to EUR 10.651m (2004: EUR 8.643m). Overview of Key Figures pursuant to IFRS (International Financial Reporting Standards): Key figures in 000s 01.01.-03.31.2005 01.01.-03.31.2004 Change Sales 10,097 7,928 +27.4% Overall performance 10,651 8,643 +23.2% EBITDA 1,412 1,070 +32.0% EBIT 1,192 863 +38.1% EBT 1,144 806 +41.9% Net income for the period 720 507 +42.0% At the end of the first quarter, STRATEC had 179 employees (2004: 158). STRATEC Biomedical Systems AG Gewerbestrasse 37 75217 Birkenfeld Deutschland ISIN: DE0007289001 WKN: 728900 Listed: Geregelter Markt in Frankfurt (Prime Standard) und Stuttgart; Freiverkehr in Berlin-Bremen, Düsseldorf und München End of ad hoc announcement (c)DGAP 26.04.2005 Issuer’s information/explanatory remarks concerning this ad hoc announcement: The more extensive interim report can be downloaded from our homepage from around 3 p.m. on Mai 11, 2005. About STRATEC Biomedical Systems AG STRATEC (http://www.stratec-biomedical.de) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems together with their own reagents to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (WKN: 728900 / ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, in the trading segment Gate- M of the Stuttgart Stock Exchange and on other exchanges. Further information can be obtained from: STRATEC Biomedical Systems AG Investor Relations André Loy Gewerbestrasse 37 75217 Birkenfeld Tel: +49 7082 7916-190 Fax: +49 7082 7916-999 E-Mail: ir@stratec-biomedical.de End of message (c)DGAP 261010 Apr 05